NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease

Author(s): Chul Ju Hwang, Dong-Young Choi, Mi Hee Park, Jin Tae Hong*.

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 18 , Issue 1 , 2019

Become EABM
Become Reviewer


Alzheimer’s disease is the most common form of dementia. It is characterized by betaamyloid peptide fibrils which are extracellular deposition of a specific protein, accompanied by extensive neuroinflammation. Various studies show the presence of a number of inflammation markers in the AD brain: elevated inflammatory cytokines and chemokines, and an accumulation of activated microglia in the damaged regions. NF-κB is a family of redox sensitive transcriptional factors, and it is known that NF-κB has binding sites in the promoter region of the genes involved in amyloidogenesis and inflammation. Long-term use of non-steroidal anti-inflammatory drugs prevents progression of AD and delays its onset, suggesting that there is a close correlation between NF-κB and AD pathogenesis. This study aims to (1) assess the association between NF-κB activity and AD through discussion of a variety of experimental and clinical studies on AD and (2) review treatment strategies designed to treat or prevent AD with NF-κB inhibitors.

Keywords: Alzheimer’s disease, amyloidogenesis, Beta-amyloid, neuroinflammation, nuclear factor kappa B, nuclear factor kappa B inhibitor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [3 - 10]
Pages: 8
DOI: 10.2174/1871527316666170807130011
Price: $95

Article Metrics

PDF: 10